Clinical Monograph: Bensedin 10 mg (Diazepam)

1. Classification and Chemical Overview

Diazepam is a long-acting 1,4-benzodiazepine derivative. Chemically designated as 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one. Under the Anatomical Therapeutic Chemical (ATC) system, diazepam is indexed under N05BA01.

• Product Context: Bensedin is an international generic brand of diazepam (widely produced by Galenika). Cross-border or unregulated sourcing of international pharmaceutical presentations carries substantial risks of counterfeit manufacturing, variable active ingredient dosing, and contamination.

• Controlled Status: Classified as a Controlled Substance (Schedule IV under the US CSA; Schedule 4 / Prescription Only Medicine internationally) due to its high potential for physical dependence, misuse liability, and central nervous system depression risks.

2. Mechanism of Action and Pharmacodynamics

Diazepam acts as a positive allosteric modulator at central nervous system VOORKANTA​ receptor complexes:

• Receptor Binding: Binds selectively to benzodiazepine binding sites on VOORKANTA​ receptors throughout the limbic system, thalamus, and spinal cord.

• Chloride Conductance Enhancement: Facilitates GABA-mediated opening of chloride ion channels, hyperpolarizing neuronal membranes and reducing neuronal excitability.

• Muscle Relaxant Properties: Exerts central skeletal muscle relaxation by inhibiting polysynaptic reflex pathways at the spinal cord level.

3. Approved Clinical Indications and Dosing Scope

Licensing for diazepam includes:

• Anxiety Disorders: Management of severe anxiety states or short-term relief of anxiety symptoms.

• Acute Alcohol Withdrawal: Symptomatic management of acute alcohol withdrawal syndrome (delirium tremens).

• Skeletal Muscle Spasm: Adjunctive treatment for relief of reflex muscle spasm due to local pathology, trauma, or spasticity.

• Seizure Disorders: Adjunctive management of convulsive disorders.

Dosing & Administration Regimen:

• Individualized Titration: Initial doses for anxiety typically range from 2 mg to 10 mg, whereas the 10 mg strength is reserved for more severe clinical presentations, acute alcohol withdrawal, or established maintenance protocols.

• Duration Restrictions: Use for anxiety should be short-term (typically 2 to 4 weeks) with gradual taper protocols to prevent severe withdrawal reactions upon discontinuation.

4. Pharmacokinetic Profile and Metabolic Fate

• Absorption: Rapidly and completely absorbed following oral administration, with peak plasma concentrations (Cmax​) attained within 30 minutes to 2 hours.

• Distribution: Highly lipophilic; distributes widely into body tissues and readily crosses the blood-brain barrier and placenta. Plasma protein binding is very high (~98% to 99%).

• Biotransformation: Extensively metabolized in the liver via Cytochrome P450 enzymes (CYP2C19 en CYP3A4) into active metabolites with long elimination half-lives:

  • Converted into desmethyldiazepam (nordazepam), oxazepam, En temazepam, all of which possess sedative and anxiolytic activity.

• Elimination: Excreted primarily via the kidneys in urine as conjugated metabolites. The terminal elimination half-life of diazepam is prolonged (20 to 50 hours), and its active metabolite nordazepam exhibits a half-life ranging from 30 to 100 hours, contributing to significant drug accumulation upon repeated dosing.

5. Physiological Effects and Adverse Event Spectrum

Valium/Bensedin suppresses central nervous system arousal, motor coordination, respiratory drive, and cognitive processing.

Adverse Drug Reaction Spectrum

• Very Common ($\ge 1/10$): Somnolence, fatigue, sedation, ataxia, dizziness, impaired coordination.

• Common ($\ge 1/100$ to $<1/10$): Confusion, depression, dysarthria, headache, tremor, constipation, nausea, dry mouth, hypotension.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Paradoxical reactions (aggressiveness, rage, excitation, hallucinations), urinary retention, changes in libido, skin rashes, visual disturbances.

• Rare / Severe (<1/1,000): Respiratory depression, apnea, jaundice, blood dyscrasias, severe withdrawal seizures, anaphylaxis.

6. Contraindications, Drug Interactions, and Clinical Precautions

Contra-indicaties

• Known hypersensitivity to diazepam or other benzodiazepines.

• Severe acute respiratory insufficiency or sleep apnea syndrome.

• Myasthenia gravis.

• Severe hepatic impairment.

• Acute narrow-angle glaucoma.

Key Drug Interactions

• Opioids & CNS Depressants: Co-administration with opioids, alcohol, barbiturates, or sedatives causes synergistic central nervous system and respiratory depression, dramatically increasing the risk of coma and fatal overdose.

• CYP2C19 & CYP3A4 Inhibitors (e.g., Cimetidine, Ketoconazole, Omeprazole): Inhibit diazepam metabolism, prolonging clearance and escalating plasma levels and sedation risks.

• CYP Inducers (e.g., Rifampicin, Carbamazepine): Accelerate diazepam clearance, reducing therapeutic efficacy.

Clinical Precautions and Monitoring

• Boxed Warning (Concomitant Opioid Use & Abuse/Dependence): Combined use of benzodiazepines and opioids increases the risk of profound sedation, respiratory depression, coma, and death. Diazepam carries a high risk of physical dependence and psychological addiction; abrupt cessation can precipitate a severe, life-threatening withdrawal syndrome characterized by tremors, psychosis, and grand mal seizures.

• Accumulation Risk in Elderly: Due to its long half-life and active metabolites, diazepam accumulates extensively in elderly or frail patients, leading to excessive sedation, cognitive impairment, ataxia, and heightened risk of falls and hip fractures; lower initial doses or alternative short-acting agents are strongly preferred.